The acoustic features of inhalation can be used to quantify aerosol delivery from a Diskus™ dry powder inhaler

Pharmaceutical Research

Volumn 31, Issue 10, 2014, Pages 2735-2747

  Seheult, Jansen N ^a   O'Connell, Peter ^b   Tee, Kee Chun ^a   Bholah, Tariq ^a   Al Bannai, Hasan ^a   Sulaiman, Imran ^a   MacHale, Elaine ^a   D'Arcy, Shona ^b   Holmes, Martin S ^b   Bergin, David ^a   Reeves, Emer ^a   Reilly, Richard B ^b   Crispino O'Connell, Gloria ^c   Ehrhardt, Carsten ^b   Healy, Anne Marie ^b   Costello, Richard W ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c StatisticaMedica   (Ireland)

Author keywords

aerosol delivery; asthma; cascade impactor; COPD; inhaler technique

Indexed keywords

AEROSOL; ANDROSTANE DERIVATIVE; DRUG COMBINATION; FLUTICASONE, SALMETEROL DRUG COMBINATION; SALBUTAMOL;

ACOUSTICS; AEROSOL; ANALOGS AND DERIVATIVES; BLOOD; DEVICES; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; EQUIPMENT DESIGN; HUMAN; INHALATION; INHALATIONAL DRUG ADMINISTRATION; INSPIRATORY CAPACITY; PHYSIOLOGY;

ACOUSTICS; ADMINISTRATION, INHALATION; AEROSOLS; ALBUTEROL; ANDROSTADIENES; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; HUMANS; INHALATION; INSPIRATORY CAPACITY;

EID: 84931090361     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1371-x     Document Type: Article

References (28)

1. Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106(1):91-101.
2. Sumby B, Cooper S, Smith I. A comparison of the inspiratory effort required to operate the Diskhaler inhaler and Turbohaler inhaler in the administration of powder drug formulations. Br J Clin Res. 1992;3:117-23.
3. Martonen B, Katz IM. Deposition patterns of aerosolised drugs within human lungs. Effects of ventilatory parameters. Pharm Res. 1993;10:871-8.
4. Chrystyn H. The Diskus™: a review of its position among dry powder inhaler devices. Int J Clin Pract. 2007;61(6):1022-36.
5. Chrystyn H, Niederlaender C. The Genuair inhaler: a novel, multi-dose dry powder inhaler. Int J Clin Pract. 2012;66(3):309-17.
6. Dunbar CA, Hickey AJ, Holder P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA Powder Part. 1998;16:45.
7. French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci. 1996;27:769-83.
8. Voss A, Finlay WA. Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm. 2002;248(1-2):39-50.
9. Burnell PK, Small T, Doig S, Johal B, Jenkins R, Gibson GJ. Ex-vivo product performance of Diskus™ and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir Med. 2001;95(5):324-30.
10. Ganderton D. General factors influencing drug delivery to the lung. Respir Med. 1997;91:13.
11. Palander A. In vitro comparison of three salbutamol-containing multidose dry powder inhalers. Clin Drug Invest. 2000;20:25-33.
12. Rottier BL, Rubin BK. Asthma medication delivery: mists and myths. Paediatr Respir Rev. 2013;14(2):112-8.
13. Behara SR, Longest PW, Farkas DR, Hindle M. Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations. J Pharm Sci. 2014;103(2):465-77.
14. Melani AS, Zanchetta D, Barbato N, Sestini P, Cinti C, Canessa PA, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol. 2004;93(5):439-46.
15. Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26(3):174-9.
16. Holmes M, Seheult J, Geraghty C, D'Arcy S, O'Brien U, Crispino O'Connell G, et al. A method of predicting inspiratory flow rate and volume from an inhaler using acoustic measurements. Physiol Meas. 2013;34:903-14.
17. Fuller R. The Diskus™: a new multi-dose powder device -efficacy and comparison with Turbuhaler™. J Aerosol Med. 1995;8(2):11-7.
18. Mahler DA, Waterman LA, Ward J, Gifford AH. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv. 2014;27(2):103-9.
19. United States Pharmacopeial Convention (USP): Chapter 601: Aerosols, metered-dose inhalers, and dry powder inhalers. In: USP36-NF31. Rockville, MD: USP; 2013;242-262
20. Grasmeijer F, Hagedoorn P, Frijlink HW, de Boer AH. Characterisation of high dose aerosols from dry powder inhalers. Int J Pharm. 2012;437(1-2):242-9.
21. Hoe S, Young PM, Chan H-K, Traini D. Introduction of the electrical Next Generation Impactor (eNGI) and investigation of its capabilities for the study of pressurized metered dose inhalers. Pharm Res. 2009;26:431-7.
22. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH, Q2 (R1). Geneva. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/Q2-R1/Step4/Q2-R1-Guideline.pdf, (2005). Accessed 4 Apr 2014.
23. International Organization for Standardization. ISO 27427. Anaesthetic and respiratory equipment - nebulizing systems and components. Geneva: International Standards Organization; 2010.
24. Inhalation Report, "How do you calculate MMAD," (2010), www.inhalationreport.com, accessed 10 Nov. 2013
25. Du XL, Zhu Z, Fu Q, Li DK, Xu WB. Pharmacokinetics and relative bioavailability of salbutamol metered-dose inhaler in healthy volunteers. Acta Pharmacol Sin. 2002;23(7):663-6.
26. Brain JD. Mechanisms of aerosol deposition and clearance. In: Moren F, Newhouse MT, Dolovich MB, editors. Aerosols in medicine. Principles, diagnosis and therapy, 2nd edn. New York: Elsevier Science Publishers (Biomedical Division); 1993. p. 351-74.
27. Hossain I, Moussavi Z. Finding the lung sound-flow relationship in normal and asthmatic subjects. In proceeding of Engineering in Medicine and Biology Society, 2004. IEMBS '04. 26th Annual International Conference of the IEEE, Volume: 2, 1-5 September 2004. Sacramento, CA, USA. Conf Proc IEEE Eng Med Biol Soc. 2004;5:3852-5.
28. Edwards AM. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. Snell NJC, Ganderton D, eds. Respir Med 1999;93:123-33. Respir Med. 2000 Sep;94(9):918-9.